 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/227841
The Pharmaceutical Market: Israel
|
Description: |
THE PHARMACEUTICAL MARKET: ISRAEL - REVIEW
The macroenvironment for the Israeli pharmaceutical industry is positive overall. Politically, the outlook remains challenging, with unrest in the Middle East posing a threat to Israel’s security. Although the Prime Minister, Binyamin Netanyahu, still retains a majority in the Knesset, after the recent departure of the Labour Party from his coalition, an election is expected to be held before it is due in 2013. Economically, Israel’s recovery from recession has been comparatively rapid, and growth in the economy is accelerating. Legally, Israel is working towards being removed from the USTR’s Priority Watch List, after agreeing to amend its IP laws. Principally, Israel has agreed to amend its patent laws and lengthen its data protection period for innovative medicines, raising data exclusivity to 6.5 years, up from the current 5.5 years. Demographically, the proportion of residents aged 65 years and over will rise to over 10% of the total population by 2016. Therefore, the population is relatively young by worldwide standards, despite having the highest proportion of over 65’s in the MEA region.
The Israeli pharmaceutical market is set to experience strong growth over the forecast period, with cost-effective generics emerging as the driving force of the market. The pharmaceutical market is dominated by generic drugs, with Teva at the forefront. Generic competition within the country has increased, with locally produced drugs as well as imported products entering the marketplace, and downward pressure on prices coming from the healthcare funds.
Israel offers first rate R&D facilities and continues to enhance its burgeoning reputation in the field of biotechnology. Teva has a biotechnology R&D site in Israel, and is currently undertaking further study with a biosimilar drug. In March 2011, XTL Biopharmaceuticals announced it was to acquire a private biotechnology company, while in August 2010, XTL completed the acquisition of an Israeli biologic company.
ENHANCED STRATEGIC INTELLIGENCE
These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included. |
|
Contents: |
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections
MACROENVIRONMENT
Political, economic, legal and demographic analysis
EPIDEMIOLOGY
Disease burden and prevalence
HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce
REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation
PRICING & REIMBURSEMENT
DISTRIBUTION CHANNELS
MARKET ANALYSIS
Projections, product development, manufacturing and trade
COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies
OTC PHARMACEUTICALS
GENERIC PHARMACEUTICALS
BIOLOGICS & BIOSIMILARS
OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis
DIRECTORY
METHODOLOGY & SOURCES |
|
Companies Mentioned |
- Bio-Dar Ltd
- Clal Pharmaceutical Resources L.P
- CTS Ltd
- Dexxon Ltd
- Kamada Ltd
- Karmat Ltd
- Koffolk Ltd
- Perrigo Israel Pharmaceuticals Ltd
- Rafa Laboratories Ltd
- Savient Pharmaceuticals
- Teva Pharmaceutical Industries Ltd
- Trima-Israel Pharmaceutical Products Ltd |
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/227841
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 13/02/2012 08:22:08 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
The Pharmaceutical Market: Israel
|
|
Web Address: |
http://www.researchandmarkets.com/reports/227841
|
|
Office Code: |
|
OC8IHINLSNNSS
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic (Online Access)
- Enterprisewide
|
|
€5,050.00
|
|
Electronic (PDF)
- Enterprisewide
|
|
€5,050.00
|
|
Electronic (Online Access)
- Single User
|
|
€775.00
|
|
Hard Copy
|
|
€775.00 + EUR€ 50.00 Shipping/Handling *
|
|
Electronic (PDF)
- Single User
|
|
€775.00
|
* Shipping/Handling is only charged once per order.
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
Page 2 of 2
Printed 13/02/2012 08:22:08
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder's Name: |
|
|
|
|
Cardholder's Signature: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
|
|
|
|
|
